NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球生長激素缺乏症市場:到 2027 年的預測

Global Growth Hormone Deficiency Market Research Report-Forecast till 2027

出版商 Market Research Future 商品編碼 1005875
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
全球生長激素缺乏症市場:到 2027 年的預測 Global Growth Hormone Deficiency Market Research Report-Forecast till 2027
出版日期: 2021年03月01日內容資訊: 英文 124 Pages
簡介

預計在 2020 年至 2027 年的回顧期內,全球生長激素缺乏症市場將以 4.2% 的複合年增長率增長,到 2027 年將達到 52.433 億美元。...全球市場增長的驅動因素是 GHD 的流行率上升、藥物上市的增加以及對該疾病認識的提高。此外,主要市場參與者對開發生長激素產品的積極承諾也有望在回顧期內推動市場增長。

市場還看到生長激素缺乏症患者數量增加,對生長激素功效的認識增加,關注 GHD 安全性和有效性的臨床試驗,以及遺傳性疾病的增加。預計市場由於與之相關的生活方式的變化,在調查期間將顯著增長。然而,高昂的治療成本和治療中使用的假冒產品越來越多,阻礙了市場的增長。另一方面,大公司與中小企業的合作以及大公司技術創新的進步,為市場提供了有利的機會。

本報告按市場規模和預測、增長和製約因素、機會和趨勢、品牌、用途、管理途徑、分銷渠道和地區調查了全球生長激素缺乏症市場和市場分析。它提供了競爭形勢等信息,以及主要公司的簡介。

主要公司

Novo Nordisk A/S、Eli Lily and Company、Novartis AG、Merck KGaA、Pfizer 等

目錄

第 1 章執行摘要

第二章市場介紹

  • 定義
  • 調查範圍
  • 調查目的
  • 市場結構
  • 先決條件和限制

第三章調查方法

  • 數據挖掘
  • 二次調查
  • 初步調查
  • 主要反應的細分
  • 預測技術
  • 調查方法市場規模預測
    • 自下而上的方法
    • 自上而下的方法
  • 數據三角戀
  • 驗證

第 4 章市場動態

  • 概述
  • 增長因素
    • 生長激素紊亂的發生率增加
    • 增加針對生長激素紊亂的臨床試驗
    • 政府針對 GHD 的舉措
    • 增加產品發佈和市場公司之間的戰略合作
  • 抑製器
    • 昂貴的 GHD 治療
    • 用於治療 GHD 的假冒產品增多
  • 市場機會
    • 強大的激素製劑產品線和電子商務平台上的易得藥品
  • 臨床試驗分析
  • 大趨勢
    • 長效重組人生長激素 (RHGH) 的進展
    • 使用 HGH 作為性能增強劑和抗衰老劑
    • 正在開發的產品
  • 宏觀經濟指標
  • 政府監管和新的處理系統
  • 長期活性生長激素(LAGH)
    • 概述
    • 開發
    • 未來產品
    • 趨勢

第五章市場因素分析

  • 供應鏈分析
    • 研發
    • 製造
    • 分發
    • 營銷和銷售
    • 售後監控
  • 波特五力模型
  • COVID-19 的影響
    • 概述
    • 對供應鏈的影響
    • 對生產的影響
  • 生長激素紊亂疾病類型的流行病學數據(2020)

第 6 章全球生長激素缺乏症市場:按品牌

  • 概述
  • 諾迪托品
  • 促性腺激素
  • HUMAT 繩索
  • SAIZEN
  • 萬能針
  • 其他

第 7 章全球生長激素缺乏症市場:按用途

  • 概述
  • 兒童生長激素缺乏症
  • 特發性身材矮小
  • 低出生體重嬰兒
  • 特納綜合症
  • 成人生長激素紊亂
  • 普拉德-威利綜合症
  • 其他

第 8 章全球生長激素缺乏症市場:按給藥途徑

  • 概述
  • 皮下
  • 肌肉注射
  • 靜脈注射

第 9 章全球生長激素缺乏症市場:按分銷渠道

  • 概述
  • 醫院藥房
  • 零售藥店
  • 診所
  • 電子商務網站

第 10 章全球生長激素缺乏症市場:按地區

  • 概述
  • 美洲
    • 北美
    • 拉丁美洲
  • 歐洲
    • 西歐
    • 東歐
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 中東和非洲
    • 中東
    • 非洲

第11章競爭形勢

  • 概述
  • 全球生長激素缺乏症市場份額分析(2020 年)
  • 競爭基準
  • 全球生長激素缺乏症市場的關鍵增長策略
  • 在全球生長激素缺乏症市場發展方面處於領先地位的公司
  • 主要發展和增長戰略
    • 擴展
    • 產品批准/FDA 批准

第12章附錄

  • 參考資料
  • 相關報導
目錄

Market Overview

Global Growth Hormone Deficiency Market is anticipated to exhibit a CAGR of 4.20% during the review period of 2020 to 2027, to surpass USD 5,243.3 Million by 2027. Growth hormone deficiency is a disease caused by the inadequacy of growth hormones in the body. Growth hormone deficiency is an endocrine disease characterized by low or deficient secretion of growth hormone. The global market growth is attributed to the rising prevalence of GHD, the growing launch of drugs by prominent market players, and growing awareness about the disease. Moreover, a growing engagement of major market players in the advancement of growth hormone products is expected to enhance the market growth during the review period.

The Global Growth Hormone Deficiency Market is estimated to register significant market growth during the review period owing to the rising number of individuals suffering from Growth Hormone Deficiency (GHD), increasing awareness regarding the effectiveness of growth hormone along with clinical trials focused on the safety and efficacy of GHD, and the changing lifestyle along with the growing prevalence of genetic disorders. However, the high cost of treatment and increasing counterfeit products being used for the treatment are restraining the market growth. On the other hand, the collaboration of major players with small players, coupled with the rise in the innovation marked by prominent players, poses lucrative opportunities for the global growth hormone deficiency market.

Market Segmentation

Global Growth Hormone Deficiency Market has been classified into Brand, Application, Distribution Channel, and Route of Administration.

Global Growth Hormone Deficiency Market has been divided into various brands such as Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and others.

Based on the application segment the global market has been classified into pediatric growth hormone deficiency, Turner syndrome, Idiopathic Short Stature (ISS), small for gestational age, adult growth hormone deficiency, Prader-Willi syndrome, and others.

In terms of route of administration, the global market has been categorized into subcutaneous, intravenous, and intramuscular.

Global Growth Hormone Market based on the distribution channel has been segmented into hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.

Regional Analysis

Global Growth Hormone Deficiency Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The Americas is divided into North America and Latin America. The Americas dominated the market in 2019 and is expected to command the market during the review period as well. The regional market growth is driven by the factors such as the rising prevalence of growth hormone deficiency, increasing applications of the hormone, and increasing awareness about the effectiveness of the hormone in short stature.

The European growth hormone deficiency market has been further bifurcated into Eastern Europe and Western Europe. Western Europe market is spread across Germany, the UK, France, Italy, and Spain. The European market is anticipated to register a substantial market of the global growth hormone deficiency owing to the increasing occurrences of growth hormone deficiencies, rising preference for growth hormones, and growing government expenditure for the healthcare sector.

Asia-Pacific is expected to be the fastest-growing market due to the rising healthcare expenditure and existence of the largest patient pool. The regional market growth is driven by the increasing investments by key market players in the region because of the growing demand.

The Middle East & Africa market is expected to register a steady market growth owing to the rising healthcare expenditure, increasing investments by major market players, and an increasing patient pool in the region.

Major Players

The Key Players in the Global Growth Hormone Deficiency Market include Novo Nordisk A/S, Eli Lily and Company, Novartis AG, Merck KGaA, and Pfizer.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION 14
  • 2.2 SCOPE OF THE STUDY 14
  • 2.3 RESEARCH OBJECTIVE 14
  • 2.4 MARKET STRUCTURE 14
  • 2.5 ASSUMPTIONS & LIMITATIONS 15

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING 16
  • 3.2 SECONDARY RESEARCH 17
  • 3.3 PRIMARY RESEARCH 17
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19
  • 3.5 FORECASTING TECHNIQUES 19
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
    • 3.6.1 BOTTOM-UP APPROACH 22
    • 3.6.2 TOP-DOWN APPROACH 22
  • 3.7 DATA TRIANGULATION 23
  • 3.8 VALIDATION 23

4 MARKET DYNAMICS

  • 4.1 OVERVIEW 24
  • 4.2 DRIVERS 25
    • 4.2.1 INCREASING INCIDENCE OF GROWTH HORMONE DEFICIENCY 25
    • 4.2.2 RISING NUMBER OF CLINICAL TRIAL FOR GH DEFICIENCY 25
    • 4.2.3 GOVERNMENT INITIATIVES FOR GHD 25
    • 4.2.4 INCREASING NUMBER OF PRODUCT LAUNCH AND STRATEGIC COLLABORATIONS AMONG MARKET PLAYERS 25
  • 4.3 RESTRAINTS 26
    • 4.3.1 HIGH COST OF GHD TREATMENT 26
    • 4.3.2 INCREASING COUNTERFEIT PRODUCTS FOR GHD TREATMENT 26
  • 4.4 OPPORTUNITIES 27
    • 4.4.1 STRONG PIPELINE OF HORMONAL DRUGS AND EASY AVAILABILITY OF PHARMA DRUGS ON E-COMMERCE PLATFORMS 27
  • 4.5 CLINICAL TRIALS ANALYSIS 27
  • 4.6 MEGATRENDS 31
    • 4.6.1 ADVENT OF LONG-ACTING RECOMBINANT HUMAN GROWTH HORMONE (RHGH) 31
    • 4.6.2 USE OF HGH AS PERFORMANCE ENHANCERS AND ANTI-AGING AGENTS 31
    • 4.6.3 PRODUCTS UNDER DEVELOPMENT 31
  • 4.7 MACROECONOMIC INDICATORS 33
  • 4.8 GOVERNMENT REGULATIONS AND NEW TREATMENT SCHEMES 33
  • 4.9 LONG ACTING GROWTH HORMONES (LAGH) 36
    • 4.9.1 OVERVIEW 36
    • 4.9.2 DEVELOPMENT 36
    • 4.9.3 UPCOMING PRODUCTS 37
    • 4.9.4 TRENDS 38

5 MARKET FACTOR ANALYSIS

  • 5.1 SUPPLY CHAIN ANALYSIS 39
    • 5.1.1 RESEARCH AND DEVELOPMENT 40
    • 5.1.2 MANUFACTURING 40
    • 5.1.3 DISTRIBUTION 40
    • 5.1.4 MARKETING AND SALES 40
    • 5.1.5 POST-SALES MONITORING 40
  • 5.2 PORTER'S FIVE FORCES MODEL 41
    • 5.2.1 THREAT OF NEW ENTRANTS 41
    • 5.2.2 BARGAINING POWER OF SUPPLIERS 41
    • 5.2.3 THREAT OF SUBSTITUTES 42
    • 5.2.4 BARGAINING POWER OF BUYERS 42
    • 5.2.5 RIVALRY 42
  • 5.3 IMPACT OF COVID-19 43
    • 5.3.1 OVERVIEW 43
    • 5.3.2 IMPACT ON SUPPLY CHAIN 43
    • 5.3.3 IMPACT ON PRODUCTION 43
  • 5.4 EPIDEMIOLOGY DATA ON TYPE OF GROWTH HORMONE DEFICIENCY DISEASES (2020) 44

6 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND

  • 6.1 OVERVIEW 47
  • 6.2 NORDITROPIN 48
  • 6.3 GENOTROPIN 48
  • 6.4 HUMATROPE 49
  • 6.5 SAIZEN 49
  • 6.6 OMNITROPE 50
  • 6.7 OTHERS 50

7 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION

  • 7.1 OVERVIEW 51
  • 7.2 PAEDIATRIC GROWTH HORMONE DEFICIENCY 52
  • 7.3 IDIOPATHIC SHORT STATURE 53
  • 7.4 SMALL FOR GESTATIONAL AGE 53
  • 7.5 TURNER SYNDROME 54
  • 7.6 ADULT GROWTH HORMONE DEFICIENCY 54
  • 7.7 PRADER-WILLI SYNDROME 55
  • 7.8 OTHERS 55

8 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION

  • 8.1 OVERVIEW 56
  • 8.2 SUBCUTANEOUS 57
  • 8.3 INTRAMUSCULAR 58
  • 8.4 INTRAVENOUS 58

9 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL

  • 9.1 OVERVIEW 60
  • 9.2 HOSPITAL PHARMACIES 61
  • 9.3 RETAIL PHARMACIES 62
  • 9.4 CLINICS 62
  • 9.5 E-COMMERCE WEBSITES 63

10 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION

  • 10.1 OVERVIEW 64
  • 10.2 AMERICAS 65
    • 10.2.1 NORTH AMERICA 68
      • 10.2.1.1 US 71
      • 10.2.1.2 CANADA 73
    • 10.2.2 LATIN AMERICA 74
  • 10.3 EUROPE 77
    • 10.3.1 WESTERN EUROPE 79
      • 10.3.1.1 GERMANY 82
      • 10.3.1.2 FRANCE 84
      • 10.3.1.3 UK 86
      • 10.3.1.4 ITALY 88
      • 10.3.1.5 SPAIN 89
      • 10.3.1.6 REST OF WESTERN EUROPE 91
    • 10.3.2 EASTERN EUROPE 93
  • 10.4 ASIA-PACIFIC 96
    • 10.4.1 JAPAN 98
    • 10.4.2 CHINA 100
    • 10.4.3 INDIA 102
    • 10.4.4 AUSTRALIA 104
    • 10.4.5 SOUTH KOREA 106
    • 10.4.6 REST OF ASIA-PACIFIC 108
  • 10.5 MIDDLE EAST & AFRICA 110
    • 10.5.1 MIDDLE EAST 112
    • 10.5.2 AFRICA 114

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW 117
  • 11.2 GLOBAL GROWTH HORMONE DEFICIENCY MARKET SHARE ANALYSIS (2020) 117
  • 11.3 COMPETITIVE BENCHMARKING 119
  • 11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET 120
  • 11.5 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET 121
  • 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 121
    • 11.6.1 EXPANSION 122
    • 11.6.2 PRODUCT APPROVAL/FDA APPROVAL 122

12 APPENDIX

  • 12.1 REFERENCES 123
  • 12.2 RELATED REPORTS 123

LIST OF TABLES

  • TABLE 9 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 19
  • TABLE 10 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR NORDITROPIN, BY REGION, 2020-2027 (USD MILLION) 20
  • TABLE 11 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR GENOTROPIN, BY REGION, 2020-2027 (USD MILLION) 20
  • TABLE 12 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR HUMATROPE, BY REGION, 2020-2027 (USD MILLION) 21
  • TABLE 13 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SAIZEN, BY REGION, 2020-2027 (USD MILLION) 21
  • TABLE 14 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR OMNITROPE, BY REGION, 2020-2027 (USD MILLION) 22
  • TABLE 15 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 24
  • TABLE 16 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR PAEDIATRIC GROWTH HORMONE DEFICIENCY, BY REGION, 2020-2027 (USD MILLION) 25
  • TABLE 17 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR IDIOPATHIC SHORT STATURE, BY REGION, 2020-2027 (USD MILLION) 25
  • TABLE 18 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SMALL FOR GESTATIONAL AGE, BY REGION, 2020-2027 (USD MILLION) 25
  • TABLE 19 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR TURNER SYNDROME, BY REGION, 2020-2027 (USD MILLION) 26
  • TABLE 20 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR ADULT GROWTH HORMONE DEFICIENCY, BY REGION, 2020-2027 (USD MILLION) 26
  • TABLE 21 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR PRADER-WILLI SYNDROME, BY REGION, 2020-2027 (USD MILLION) 27
  • TABLE 22 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 28
  • TABLE 23 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SUBCUTANEOUS, BY REGION, 2020-2027 (USD MILLION) 29
  • TABLE 24 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR INTRAMUSCULAR, BY REGION, 2020-2027 (USD MILLION) 29
  • TABLE 25 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR INTRAVENOUS, BY REGION, 2020-2027 (USD MILLION) 30
  • TABLE 26 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 31
  • TABLE 27 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020-2027 (USD MILLION) 32
  • TABLE 28 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR RETAIL PHARMACIES, BY REGION, 2020-2027 (USD MILLION) 32
  • TABLE 29 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR CLINICS, BY REGION, 2020-2027 (USD MILLION) 33
  • TABLE 30 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR E-COMMERCE WEBSITES, BY REGION, 2020-2027 (USD MILLION) 33
  • TABLE 31 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020-2027 (USD MILLION) 35
  • TABLE 32 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020-2027 (USD MILLION) 36
  • TABLE 33 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 36
  • TABLE 34 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 37
  • TABLE 35 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 37
  • TABLE 36 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 38
  • TABLE 37 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 39
  • TABLE 38 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 39
  • TABLE 39 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 39
  • TABLE 40 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 40
  • TABLE 41 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 40
  • TABLE 42 US: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 41
  • TABLE 43 US: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 41
  • TABLE 44 US: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 42
  • TABLE 45 US: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 42
  • TABLE 46 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 43
  • TABLE 47 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 43
  • TABLE 48 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 44
  • TABLE 49 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 44
  • TABLE 50 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 45
  • TABLE 51 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 45
  • TABLE 52 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 46
  • TABLE 53 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 46
  • TABLE 54 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020-2027 (USD MILLION) 47
  • TABLE 55 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 47
  • TABLE 56 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 48
  • TABLE 57 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 48
  • TABLE 58 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 49
  • TABLE 59 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 50
  • TABLE 60 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 50
  • TABLE 61 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 51
  • TABLE 62 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 51
  • TABLE 63 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 52
  • TABLE 64 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 52
  • TABLE 65 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 52
  • TABLE 66 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 53
  • TABLE 67 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 53
  • TABLE 68 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 54
  • TABLE 69 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 54
  • TABLE 70 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 55
  • TABLE 71 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 55
  • TABLE 72 UK: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 56
  • TABLE 73 UK: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 56
  • TABLE 74 UK: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 57
  • TABLE 75 UK: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 57
  • TABLE 76 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 58
  • TABLE 77 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 58
  • TABLE 78 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 59
  • TABLE 79 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 59
  • TABLE 80 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 59
  • TABLE 81 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 60
  • TABLE 82 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 61
  • TABLE 83 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 61
  • TABLE 84 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 61
  • TABLE 85 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 62
  • TABLE 86 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 62
  • TABLE 87 REST OF WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 63
  • TABLE 88 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 63
  • TABLE 89 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 64
  • TABLE 90 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 64
  • TABLE 91 EASTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 65
  • TABLE 92 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 66
  • TABLE 93 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 67
  • TABLE 94 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 67
  • TABLE 95 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 68
  • TABLE 96 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 68
  • TABLE 97 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 68
  • TABLE 98 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 69
  • TABLE 99 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 69
  • TABLE 100 JAPAN: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 70
  • TABLE 101 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 70
  • TABLE 102 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 71
  • TABLE 103 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 71
  • TABLE 104 CHINA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 72
  • TABLE 105 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 72
  • TABLE 106 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 73
  • TABLE 107 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 73
  • TABLE 108 INDIA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 74
  • TABLE 109 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 74
  • TABLE 110 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 75
  • TABLE 111 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 75
  • TABLE 112 AUSTRALIA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 75
  • TABLE 113 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 76
  • TABLE 114 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 76
  • TABLE 115 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 77
  • TABLE 116 SOUTH KOREA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 77
  • TABLE 117 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 78
  • TABLE 118 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 78
  • TABLE 119 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 79
  • TABLE 120 REST OF ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 79
  • TABLE 121 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020-2027 (USD MILLION) 80
  • TABLE 122 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 81
  • TABLE 123 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 81
  • TABLE 124 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 82
  • TABLE 125 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 82
  • TABLE 126 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 83
  • TABLE 127 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 83
  • TABLE 128 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 84
  • TABLE 129 MIDDLE EAST: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 84
  • TABLE 130 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020-2027 (USD MILLION) 84
  • TABLE 131 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 85
  • TABLE 132 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION) 85
  • TABLE 133 AFRICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION) 86

LIST OF FIGURES

  • FIGURE 1 MARKET DYNAMICS: GLOBAL GROWTH HORMONE DEFICIENCY MARKET 12
  • FIGURE 2 DRIVERS: IMPACT ANALYSIS 14
  • FIGURE 3 RESTRAINTS: IMPACT ANALYSIS 14
  • FIGURE 1 ONGOING CLINICAL TRIALS PHASES (%) 18
  • FIGURE 2 SUPPLY CHAIN ANALYSIS: GLOBAL GROWTH HORMONE DEFICIENCY MARKET 27
  • FIGURE 3 PORTER'S FIVE FORCES MODEL 29
  • FIGURE 4 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2020 AND 2027 (USD MILLION) 35
  • FIGURE 5 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2020 AND 2027 (USD MILLION) 39
  • FIGURE 6 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2020 AND 2027 (USD MILLION) 44
  • FIGURE 7 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2020 AND 2027 (USD MILLION) 48
  • FIGURE 8 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 52
  • FIGURE 9 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY REGION, 2020 (%) 53
  • FIGURE 10 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY COUNTRY, 2020 (%) 56
  • FIGURE 11 EUROPE: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY REGION, 2020 (%) 65
  • FIGURE 12 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY COUNTRY, 2020 (%) 67
  • FIGURE 13 ASIA-PACIFIC: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY COUNTRY, 2020 (%) 84
  • FIGURE 14 MIDDLE EAST & AFRICA: GROWTH HORMONE DEFICIENCY MARKET SHARE, BY REGION, 2020 (%) 98
  • FIGURE 15 BENCHMARKING OF MAJOR COMPETITORS 107
  • FIGURE 16 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET 108
  • FIGURE 17 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, KEY DEVELOPMENTS & GROWTH STRATEGIES (%) 109